These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 15759282)

  • 21. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
    Otto Buczkowska E; Dworzecki T
    Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
    Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
    J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
    Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M
    Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New insights into the regulation of glucagon secretion by glucagon-like peptide-1.
    Gromada J; Rorsman P
    Horm Metab Res; 2004; 36(11-12):822-9. PubMed ID: 15655714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On the physiology of GIP and GLP-1.
    Holst JJ
    Horm Metab Res; 2004; 36(11-12):747-54. PubMed ID: 15655703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biology of incretin hormones.
    Drucker DJ
    Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.
    Nauck MA
    Acta Diabetol; 1998 Oct; 35(3):117-29. PubMed ID: 9840447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incretin hormones--an update.
    Holst JJ; Orskov C
    Scand J Clin Lab Invest Suppl; 2001; 234():75-85. PubMed ID: 11713984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
    Meier JJ; Gallwitz B; Nauck MA
    BioDrugs; 2003; 17(2):93-102. PubMed ID: 12641488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GLP-1 and extra-islet effects.
    Ahrén B
    Horm Metab Res; 2004; 36(11-12):842-5. PubMed ID: 15655717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.
    Hui H; Zhao X; Perfetti R
    Diabetes Metab Res Rev; 2005; 21(4):313-31. PubMed ID: 15852457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum.
    Hansen L; Hartmann B; Mineo H; Holst JJ
    Regul Pept; 2004 Apr; 118(1-2):11-8. PubMed ID: 14759551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism.
    D'Alessio D; Vahl T; Prigeon R
    Horm Metab Res; 2004; 36(11-12):837-41. PubMed ID: 15655716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide.
    Meier JJ; Nauck MA
    Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):587-606. PubMed ID: 15533777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.